Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06592638 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Dose Escalation Study of ZG006 in Patients With Small Cell Lung Cancer
A Phase 1 study of Small-cell Lung Cancer, sponsored by Suzhou Zelgen Biopharmaceuticals Co..
- Recruiting
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 6
- Study locations
NCT06592638: Recruiting Phase 1 study of Small-cell Lung Cancer, sponsored by Suzhou Zelgen Biopharmaceuticals Co..
NCT06592638 is a Phase 1 study of Small-cell Lung Cancer that is actively recruiting participants, run by Suzhou Zelgen Biopharmaceuticals Co.. The registered enrollment target is 30 participants, below the 232-participant average among 79 other Small-cell Lung Cancer trials with a reported enrollment target (87% lower). The trial reports 6 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06592638, a Phase 1 study of Small-cell Lung Cancer, is actively recruiting participants, sponsored by Suzhou Zelgen Biopharmaceuticals Co..
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 6
- Study locations
Study Summary
This is a multi-center, open-label, Phase 1 clinical study of ZG006 in the US for the treatment of subjects with small cell lung cancer who have failed or are intolerant to available standard treatment. During the dose escalation stage, a standard "3+3" design will be used to assess the MTD/ recommended dose for the subsequent studies.
Primary Outcome
An event is considered to be a DLT if the event occurs within the first 28 days of treatment and meets the dose-limiting toxicity criteria
Conditions Studied
Interventions
- DRUG ZG006
Study Locations (6)
Ohio
- Zelgen Site 101 - Canton
- Zelgen Site 104 - Cleveland
California
- Zelgen Site 105 - Orange
Florida
- Zelgen Site 102 - Plantation
Kentucky
- Zelgen Site 103 - Lexington
Texas
- Zelgen Site 106 - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-03-31 |
| Est. Completion | 2027-06 |
| Phase | Phase 1 |
What NCT06592638 shows while recruiting
NCT06592638 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 232-participant average among 79 other Small-cell Lung Cancer trials with a reported enrollment target (87% lower).
The record links to 1 condition, with Small-cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which ZG006 is the first listed.
NCT06592638 lists 6 locations in 5 states (Ohio, California, Florida).
Frequently Asked Questions
What is clinical trial NCT06592638 about?
NCT06592638 is a clinical study titled "A Phase 1 Dose Escalation Study of ZG006 in Patients With Small Cell Lung Cancer". This is a multi-center, open-label, Phase 1 clinical study of ZG006 in the US for the treatment of subjects with small cell lung cancer who have failed or are intolerant to available standard treatment. During the dose escalation stage, a standard "3+3" design will be used to assess the MTD/ recomme...
What is the current status of trial NCT06592638?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2025-03-31. Estimated completion is 2027-06.
What conditions does trial NCT06592638 study?
This clinical trial studies the following conditions: Small-cell Lung Cancer.
What interventions are being tested in trial NCT06592638?
The interventions under investigation include: ZG006 (DRUG).
Who is sponsoring clinical trial NCT06592638?
This trial is sponsored by Suzhou Zelgen Biopharmaceuticals Co., which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06592638 being conducted?
This trial has 6 study locations across California, Florida, Kentucky, Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Small-cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06592638's enrollment target sits among peer trials
30 66th of 79 higher than 8 of 79 other Small-cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Small-cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of MGC026 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Small Cell Lung Cancer Irinotecan and CDC2-like Kinase Inhibition Trial (SLICK Trial)
RECRUITING · Phase 1
-
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
RECRUITING · Phase 1
-
Study of NMS-03305293 in Adult Patient With Relapsed Small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI